Safe vaccination of children with a virosomal adjuvanted influenza vaccine.
Identifieur interne : 000401 ( Main/Exploration ); précédent : 000400; suivant : 000402Safe vaccination of children with a virosomal adjuvanted influenza vaccine.
Auteurs : Valérie Künzi [Suisse] ; Martin Dornseiff ; Jörg Horwath ; Katharina HartmannSource :
- Vaccine [ 0264-410X ] ; 2009.
Descripteurs français
- KwdFr :
- Allemagne (MeSH), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Enquêtes et questionnaires (MeSH), Humains (MeSH), Nourrisson (MeSH), Surveillance post-commercialisation des produits de santé (MeSH), Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (immunologie), Vaccins à virosomes (effets indésirables), Vaccins à virosomes (immunologie).
- MESH :
- effets indésirables : Vaccins antigrippaux, Vaccins à virosomes.
- immunologie : Vaccins antigrippaux, Vaccins à virosomes.
- Allemagne, Enfant, Enfant d'âge préscolaire, Enquêtes et questionnaires, Humains, Nourrisson, Surveillance post-commercialisation des produits de santé.
- Wicri :
- geographic : Allemagne.
English descriptors
- KwdEn :
- Child (MeSH), Child, Preschool (MeSH), Germany (MeSH), Humans (MeSH), Infant (MeSH), Influenza Vaccines (adverse effects), Influenza Vaccines (immunology), Product Surveillance, Postmarketing (MeSH), Surveys and Questionnaires (MeSH), Vaccines, Virosome (adverse effects), Vaccines, Virosome (immunology).
- MESH :
- chemical , adverse effects : Influenza Vaccines, Vaccines, Virosome.
- chemical , immunology : Influenza Vaccines, Vaccines, Virosome.
- geographic : Germany.
- Child, Child, Preschool, Humans, Infant, Product Surveillance, Postmarketing, Surveys and Questionnaires.
Abstract
A post-marketing study was conducted in 26 paediatric practices in Germany to collect safety information on the virosomal adjuvanted influenza vaccine Inflexal V (in Germany marketed as Infectovac Flu). Children aged 6 months to 6 years received one or two doses. Adverse events were documented by parents/legal guardians in a questionnaire for four days after vaccination. The rates of adverse events were low: 14% of vaccine exposures were associated with systemic and 25% with local adverse events. Most symptoms were mild to moderate and resolved within a few days. Nearly 100% of parents/legal guardians would agree to have their child vaccinated again with Inflexal V. Vaccination with Inflexal V was safe, well tolerated and highly accepted by parents/legal guardians.
DOI: 10.1016/j.vaccine.2008.12.008
PubMed: 19114080
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safe vaccination of children with a virosomal adjuvanted influenza vaccine.</title><author><name sortKey="Kunzi, Valerie" sort="Kunzi, Valerie" uniqKey="Kunzi V" first="Valérie" last="Künzi">Valérie Künzi</name><affiliation wicri:level="1"><nlm:affiliation>Crucell, Berna Biotech Ltd, Rehhagstrasse 79, 3018 Berne, Switzerland. valerie.kuenzi@crucell.ch</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Crucell, Berna Biotech Ltd, Rehhagstrasse 79, 3018 Berne</wicri:regionArea><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Dornseiff, Martin" sort="Dornseiff, Martin" uniqKey="Dornseiff M" first="Martin" last="Dornseiff">Martin Dornseiff</name></author><author><name sortKey="Horwath, Jorg" sort="Horwath, Jorg" uniqKey="Horwath J" first="Jörg" last="Horwath">Jörg Horwath</name></author><author><name sortKey="Hartmann, Katharina" sort="Hartmann, Katharina" uniqKey="Hartmann K" first="Katharina" last="Hartmann">Katharina Hartmann</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19114080</idno><idno type="pmid">19114080</idno><idno type="doi">10.1016/j.vaccine.2008.12.008</idno><idno type="wicri:Area/Main/Corpus">000431</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000431</idno><idno type="wicri:Area/Main/Curation">000431</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000431</idno><idno type="wicri:Area/Main/Exploration">000431</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Safe vaccination of children with a virosomal adjuvanted influenza vaccine.</title><author><name sortKey="Kunzi, Valerie" sort="Kunzi, Valerie" uniqKey="Kunzi V" first="Valérie" last="Künzi">Valérie Künzi</name><affiliation wicri:level="1"><nlm:affiliation>Crucell, Berna Biotech Ltd, Rehhagstrasse 79, 3018 Berne, Switzerland. valerie.kuenzi@crucell.ch</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Crucell, Berna Biotech Ltd, Rehhagstrasse 79, 3018 Berne</wicri:regionArea><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Dornseiff, Martin" sort="Dornseiff, Martin" uniqKey="Dornseiff M" first="Martin" last="Dornseiff">Martin Dornseiff</name></author><author><name sortKey="Horwath, Jorg" sort="Horwath, Jorg" uniqKey="Horwath J" first="Jörg" last="Horwath">Jörg Horwath</name></author><author><name sortKey="Hartmann, Katharina" sort="Hartmann, Katharina" uniqKey="Hartmann K" first="Katharina" last="Hartmann">Katharina Hartmann</name></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Child (MeSH)</term><term>Child, Preschool (MeSH)</term><term>Germany (MeSH)</term><term>Humans (MeSH)</term><term>Infant (MeSH)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza Vaccines (immunology)</term><term>Product Surveillance, Postmarketing (MeSH)</term><term>Surveys and Questionnaires (MeSH)</term><term>Vaccines, Virosome (adverse effects)</term><term>Vaccines, Virosome (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Allemagne (MeSH)</term><term>Enfant (MeSH)</term><term>Enfant d'âge préscolaire (MeSH)</term><term>Enquêtes et questionnaires (MeSH)</term><term>Humains (MeSH)</term><term>Nourrisson (MeSH)</term><term>Surveillance post-commercialisation des produits de santé (MeSH)</term><term>Vaccins antigrippaux (effets indésirables)</term><term>Vaccins antigrippaux (immunologie)</term><term>Vaccins à virosomes (effets indésirables)</term><term>Vaccins à virosomes (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Virosome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Virosome</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Germany</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins à virosomes</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins à virosomes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Child</term><term>Child, Preschool</term><term>Humans</term><term>Infant</term><term>Product Surveillance, Postmarketing</term><term>Surveys and Questionnaires</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Allemagne</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Enquêtes et questionnaires</term><term>Humains</term><term>Nourrisson</term><term>Surveillance post-commercialisation des produits de santé</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A post-marketing study was conducted in 26 paediatric practices in Germany to collect safety information on the virosomal adjuvanted influenza vaccine Inflexal V (in Germany marketed as Infectovac Flu). Children aged 6 months to 6 years received one or two doses. Adverse events were documented by parents/legal guardians in a questionnaire for four days after vaccination. The rates of adverse events were low: 14% of vaccine exposures were associated with systemic and 25% with local adverse events. Most symptoms were mild to moderate and resolved within a few days. Nearly 100% of parents/legal guardians would agree to have their child vaccinated again with Inflexal V. Vaccination with Inflexal V was safe, well tolerated and highly accepted by parents/legal guardians.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19114080</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0264-410X</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>8</Issue><PubDate><Year>2009</Year><Month>Feb</Month><Day>18</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Safe vaccination of children with a virosomal adjuvanted influenza vaccine.</ArticleTitle><Pagination><MedlinePgn>1261-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2008.12.008</ELocationID><Abstract><AbstractText>A post-marketing study was conducted in 26 paediatric practices in Germany to collect safety information on the virosomal adjuvanted influenza vaccine Inflexal V (in Germany marketed as Infectovac Flu). Children aged 6 months to 6 years received one or two doses. Adverse events were documented by parents/legal guardians in a questionnaire for four days after vaccination. The rates of adverse events were low: 14% of vaccine exposures were associated with systemic and 25% with local adverse events. Most symptoms were mild to moderate and resolved within a few days. Nearly 100% of parents/legal guardians would agree to have their child vaccinated again with Inflexal V. Vaccination with Inflexal V was safe, well tolerated and highly accepted by parents/legal guardians.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Künzi</LastName><ForeName>Valérie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Crucell, Berna Biotech Ltd, Rehhagstrasse 79, 3018 Berne, Switzerland. valerie.kuenzi@crucell.ch</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dornseiff</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Horwath</LastName><ForeName>Jörg</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hartmann</LastName><ForeName>Katharina</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017429">Clinical Trial, Phase IV</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>12</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475022">Inflexal V</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022721">Vaccines, Virosome</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="N">Product Surveillance, Postmarketing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022721" MajorTopicYN="N">Vaccines, Virosome</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>07</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>12</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>12</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19114080</ArticleId><ArticleId IdType="pii">S0264-410X(08)01729-5</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2008.12.008</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Suisse</li></country><region><li>Canton de Berne</li></region><settlement><li>Berne</li></settlement></list><tree><noCountry><name sortKey="Dornseiff, Martin" sort="Dornseiff, Martin" uniqKey="Dornseiff M" first="Martin" last="Dornseiff">Martin Dornseiff</name><name sortKey="Hartmann, Katharina" sort="Hartmann, Katharina" uniqKey="Hartmann K" first="Katharina" last="Hartmann">Katharina Hartmann</name><name sortKey="Horwath, Jorg" sort="Horwath, Jorg" uniqKey="Horwath J" first="Jörg" last="Horwath">Jörg Horwath</name></noCountry><country name="Suisse"><region name="Canton de Berne"><name sortKey="Kunzi, Valerie" sort="Kunzi, Valerie" uniqKey="Kunzi V" first="Valérie" last="Künzi">Valérie Künzi</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000401 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000401 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeAllemagneV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:19114080
|texte= Safe vaccination of children with a virosomal adjuvanted influenza vaccine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19114080" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV4
| This area was generated with Dilib version V0.6.35. |  |